Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Seres Therapeutics Inc MCRB

Healthcare Biotechnology
Seres Therapeutics, Inc. is a commercial-stage microbiome therapeutics company. It is focused on the development and commercialization of a novel class of biological drugs, which are designed to treat disease by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. Its lead program, VOWST, is to prevent recurrence of... see more

Recent & Breaking News (NDAQ:MCRB)

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Regarding Possible Violations of Federal Securities Laws by Certain Officers and Directors of Seres Therapeutics, Inc.

Business Wire August 1, 2016

10 Biggest Mid-Day Losers For Monday

Benzinga.com  August 1, 2016

SHAREHOLDER ALERT: Goldberg Law PC Announces an Investigation of Claims against Seres Therapeutics, Inc. and Advises Investors with Losses to Contact the Firm

Business Wire August 1, 2016

INVESTOR ALERT: Hagens Berman Alerts Investors in Seres Therapeutics, Inc. (NASDAQ: MCRB) to Investigation into Possible Securities Law Violations

Business Wire August 1, 2016

15 Stocks Moving In Monday's Pre-Market Session

Benzinga.com  August 1, 2016

Mid-Afternoon Market Update: Crude Oil Up 1.1%; Cloud Peak Energy Shares Surge Following Earnings Beat

Benzinga.com  July 29, 2016

15 Biggest Mid-Day Losers For Friday

Benzinga.com  July 29, 2016

15 Stocks Moving In Friday's Pre-Market Session

Benzinga.com  July 29, 2016

Seres Therapeutics Announces Interim Results from SER-109 Phase 2 ECOSPOR Study in Multiply Recurrent Clostridium difficile Infection

Business Wire July 29, 2016

Seres Therapeutics and Emulate Announce Collaboration to Support the Development of Novel Microbiome Therapeutics for Inflammatory Bowel Disease and other Serious Conditions

Business Wire July 12, 2016

Seres Therapeutics Announces Initiation of a Phase 1b Clinical Trial of SER-262 for Primary Clostridium difficile Infection

Business Wire July 7, 2016

Flagship Ventures Names Daniel McIntyre Partner

PR Newswire June 29, 2016

Seres Therapeutics Announces Collaboration with Massachusetts General Hospital to Identify Microbiome Therapeutics for Obesity and Metabolic Syndrome

Business Wire June 22, 2016

Seres Therapeutics Presents New Data at ASM Microbe 2016, including Characterization of SER-262, the Rationally-Designed, Fermented Microbiome Therapeutic Candidate for Primary Clostridium difficile Infection

Business Wire June 20, 2016

The Market In 5 Minutes: Float Like A Butterfly, Sting Like A Bee

Benzinga.com  June 6, 2016

Seres Therapeutics Announces Research Collaboration with Mayo Clinic to Identify Microbiome Therapeutics for Primary Sclerosing Cholangitis, Non-Alcoholic Steatohepatitis (NASH) and Other Liver Diseases

Business Wire June 6, 2016

Seres Therapeutics to Present at Goldman Sachs 37th Annual Global Healthcare Conference

Business Wire June 2, 2016